Vi­a­tris li­cens­es Idor­sia’s PhI­II heart and lu­pus drugs with $350M up­front

Vi­a­tris has inked a deal with Idor­sia for a pair of late-stage drug can­di­dates in a move that may re­flect Vi­a­tris’ ef­forts to build its prod­uct de­vel­op­ment mus­cle.

The de­vel­op­ment and com­mer­cial­iza­tion part­ner­ship is based on two Phase III as­sets: P2Y12 in­hibitor se­latogrel for acute my­ocar­dial in­farc­tion and S1P1 re­cep­tor mod­u­la­tor cene­r­i­mod for sys­temic lu­pus ery­the­mato­sus (SLE). Vi­a­tris al­so has the right of first ne­go­ti­a­tion and first re­fusal for cer­tain oth­er Idor­sia as­sets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER